The development and progression of thyroid tumors is signaled by phenotype-specific mutations of genes involved in growth control. Molecular events associated with undifferentiated thyroid cancer are not known. We examined normal, benign, and malignant thyroid tissue for structural abnormalities of the p53 tumor suppressor gene. Mutations were detected by singlestrand conformation polymorphisms of PCR-amplified DNA, using primers bracketing the known hot spots on either exons 5, 6, 7, or 8. The prevalence of mutations was as follows: normal thyroid 0/6; follicular adenomas 0/31; papillary carcinomas 0/37; medullary carcinomas 0/2; follicular carcinomas 1/11; anaplastic carcinomas 5/6; thyroid carcinoma cell lines 3/4. Positive cases were confirmed by direct sequencing of the PCR products. All five anaplastic carcinoma tissues and the anaplastic carcinoma cell line ARO had G:C to A:T transitions leading to an Arg to His substitution at codon 273. In both tumors and cell lines, examples of heterozygous and homozygous p53 mutations were identified. The only thyroid carcinoma cell line in which p53 mutations were not detected in exons 5-8 had markedly decreased p53 mRNA levels, suggesting the presence of a structural abnormality of either p53 itself or of some factor controlling its expression. The presence of p53 mutations almost exclusively in poorly differentiated thyroid tumors and thyroid cancer cell lines suggests that inactivation of p53 may confer these neoplasms with aggressive properties, and further loss of differentiated function. (J. Clin. Invest. 1993. 91:179-184.)
Introduction
Thyroid nodules develop in up to 10% of adults during their lifetime. Presently available diagnostic approaches often do not discriminate benign from malignant follicular neoplasms preoperatively, nor do they accurately predict clinical behavior. Tumors of follicular thyroid cells represent an interesting model ofepithelial cell transformation. They comprise a broad spectrum of neoplastic phenotypes, which include benign and nonprogressive macrofollicular adenomas, microfollicular adenomas, well-differentiated follicular and papillary carcinomas, and the invasive and always fatal anaplastic carcinomas (1) . The sequence of somatic cell mutations which underlie these different tumor cell types is gradually becoming unraveled (2) (3) (4) (5) (6) (7) (8) (9) . Activating point mutations of ras oncogenes are probably an early event in thyroid tumor formation, in that they occur with similar prevalence in benign and malignant thyroid tumors (3) (4) (5) (6) . Allelic losses ofchromosome 11 q 13, a region containing a number of genes involved in growth control, including the putative gene predisposing to multiple endocrine neoplasia type I, are found in follicular but not papillary thyroid tumors (7) , suggesting that loss of a tumor suppressor gene at this locus may direct progression towards the follicular phenotype. In contrast, the PTC oncogene, which results from an intrachromosomal inversion in lOq, leads to the activation of the ret proto-oncogene and is unique to papillary carcinomas (8) . Recently, Herrmann et al. (9) reported loss ofheterozygosity for loci on chromosome 3p associated with follicular carcinomas. No information exists concerning either the molecular genetics ofanaplastic thyroid carcinomas, or events which may be involved in the transition to this aggressive form of the disease. p53 is a nuclear protein which appears to play a role in the regulatory control of normal cellular proliferation ( 10 Nucleic acid extraction. RNA and DNA were extracted from a cesium chloride ultracentrifugation gradient as described (29) . The RNA pellet was rinsed in 80% ethanol and then resuspended in diethylpyrocarbonate-treated H20. The DNA layer was immediately precipitated in 2.5 vol of ethanol and recovered by spooling. The DNA pellet was then rinsed in 10 ml of 80% ethanol and recovered by centrifugation at 3,000 g at room temperature. DNA was then digested at 55°C overnight with 1 mg/ml proteinase K in a buffer containing 150 mM NaCl, 10 mM Tris, pH 7.5, 10 mM ethylene diaminotetraacetic acid (EDTA), and 0.5% sodium dodecyl sulfate (SDS). The mixture was then phenol-chloroform extracted. Sodium acetate (final concentration 0.3 M) was added to the aqueous layer, which was then ethanol precipitated. DNA was pelleted, air-dried, and resuspended in H20. After quantification by absorption at 260 nm, extracts were stored until assayed (RNA at -70°C, DNA at -20°C). For extraction of DNA from paraffin-embedded anaplastic carcinomas, 60 MM sections were deparaffinized in 0.5 ml of xylene, and then ethanol precipitated. Samples were incubated in 100 mM Tris Cl, 4 mM EDTA, pH 8.0, and 1 mg/ ml proteinase K for 12 h at 37°C, boiled for 7 min, and microfuged to remove residual material. 1-10-,ul aliquots were used as templates for polymerase chain reaction (PCR).' Northern gel electrophoresis. Gel electrophoresis of 20 Mg of total RNA was performed on 1% agarose gels containing 2.2 M formaldehyde, as previously described (30) . The filters were hybridized in a buffer containing 50% formamide, 5x SSPE (43.8 g/liter NaCl, 6.9 g/liter NaH2PO4-H20, and 1.85 g/liter EDTA), 5x Denhardt's solution (1 g/liter polyvinyl-pyrrolidone, 1 g/liter bovine serum albumin, and 1 g/liter Ficoll 400), 0.1% SDS, and 200 Mg/ml salmon sperm DNA for 48 h at 42°C with 32P-labeled DNA probes. Probes were labeled with [a32P]dCTP using the random primer technique (31) following the manufacturer's protocol (Stratagene, Inc., La Jolla, CA). The following human probes were used: p53 cDNA pR42 (Nco 500-bp fragment) (32), y-actin cDNA pHF y-A-1 (33) . After hybridization the filters were washed twice in 2x SSC (0.3 M NaCl and 30 mM sodium citrate), 0.1% SDS at room temperature, and then twice in 0.1 x SSC, 0.1% SDS at 55°C. Blots were then exposed to XAR-5 film (Eastman Kodak Co., Rochester, NY) for autoradiography for 12-72 h at -700C.
Single-strand conformation polymorphism (SSCP) analysis. SSCP analysis was performed using a modification of a previously reported method (34, 35) . DNA specimens were coded, and the operator was blinded to the histological diagnoses of the samples. Direct sequencing. Direct sequencing of the PCR products was done using the Sequenase Kit (U.S. Biochemicals, Cleveland, OH) with T7 polymerase, after making the PCR product single-stranded with T7 exonuclease (U.S. Biochemicals).
Results
About 98% of single base-substitution mutations of the coding region of p53 in human cancers occur within a 540-bp stretch between codons 126-306, corresponding to exons 5-8 (37) . DNA from thyroid tissues and thyroid cancer cell lines was screened for mutations within this region by SSCP. Intronic primers flanking the individual exons were used to amplify the template DNA in the presence of [32-P]CTP (Fig. 1) . SSCP analysis of four clonal human thyroid cancer cell lines is shown in Fig. 2 A. Positive samples showed a shift in mobility ofone of the labeled strands. In certain cases, SSCP analysis can simultaneously establish whether a sample has lost one allele and harbors a mutation in the remaining one (34) . This is particularly applicable to clonal cell lines. In the SSCP analysis for exon (Fig. 3) .
Discussion
To obtain evidence for a role of tumor suppressor genes in human thyroid tumorigenesis, we recently reported studies on a large number of thyroid tumors screened for loss of genetic material using highly polymorphic markers for serveral nonacrocentric chromosome arms. Contrary to observations in other forms of neoplasia, we found a low prevalence of genetic loss, which was largely confined to a locus on chromosome 11 q 1 3 in follicular neoplasms (7), Interestingly, none ofthe 33 informative cases of benign and differentiated thyroid neoplasms had loss of heterozygosity for the chromosome 1 7p marker YNZ22, which is closely adjacent to the p53 gene. In the above study, anaplastic carcinomas and thyroid carcinoma cell lines were not examined because of a lack of constitutional DNA from the affected individuals. We were prompted to consider further a role for p53 in anaplastic carcinomas because of the high prevalence of mutations of this gene in other forms of aggressive cancer. In addition, mice expressing SV40 large and small T antigen transgenes in thyroid cells have been reported to develop undifferentiated carcinomas (24) , further suggesting a role for p53 in malignant thyroid cancer. We used SSCP analysis to screen for base substitution mutations (34) . None of the benign follicular adenomas and differentiated papillary carcinomas and only 1 / 11 follicular carcinomas had p53 abnormalities by SSCP. In contrast, we found altered p53 strand migration patterns confined almost exclusively to poorly differentiated thyroid carcinomas and thyroid carcinoma cell lines. A singular feature was that all positive anaplastic carcinomas and the anaplastic carcinoma cell line ARO had codon 273 G:C to A:T transitions. As opposed to ras oncogenes, which are also frequent targets ofmutations in neoplasia, p53 mutations in human cancers occur at multiple sites (Table I ).
in the evolutionarily conserved domains ofthe protein (37) . A remarkable exception to this pattern has been reported in hepatocellular carcinomas, in which G:C to T:A codon 249 transversions were highly predominant ( 19, 20) . These tumors were from patients from geographical regions where aflatoxin B 1 is a common food contaminant. This carcinogen causes frequent G to T transversions in mutational assays, and could account for the selectivity of p53 mutations in hepatocellular carcinomas. In non-small cell lung cancer, p53 G:C to T:A transversions were also common, but these were distributed among many different codons (37, 38) . Of note is that environmental carcinogens, such as benzo(a)pyrene present in tobacco smoke, are associated with G to T transversions (39) . DNA mutations can arise through two major pathways. Firstly, they may be caused by exogenous factors, in which the environmental agent determines the nature of DNA damage. Alternatively, they may result from errors in mechanisms controlling metabolism of nucleic acids. CpG dinucleotides are frequent targets ofthis latter type ofmutation (40) . The transition observed in all positive anaplastic thyroid carcinoma samples involved a CpG mutation. Because the cytosine in the CpG dinucleotide on codon 273 has been found to be methylated in vivo (41 ) , the high mutation rate at this site in these tumors could be due to deamination of the methylated cytosine and replacement by a thymidine (41 ) .
While this work was in progress, Wright et al. (42) reported a codon 273 transitional mutation in a human follicular thyroid carcinoma cell line. Contrary to our findings, they did not encounter p53 mutations within exons 5, 7, and 8, or increased p53 immunostaining in any offour anaplastic carcinomas. The significance of this discrepancy is unclear, but could indicate true regional differences, confounding effects ofcontamination with normal cells within the tissue sections, or mutations at other sites in the gene (i.e., exon 6) which were not examined.
Mutations in different locations of p53 may lead to distinct biological effects. The allele mutant for residue 175 is 3-10-fold more efficient than the mutant for residue 273 in cooperating with ras to transform primary rat cells in culture ( 10, 43) . The p53 mutants at residues 135 and 175 also show evidence of changes in p53 protein conformation, in that they are not recognized by specific monoclonal antibodies, and they form complexes with heat shock protein 70, whereas mutant 273 does not ( 10, 44) . There is controversy as to whether various mutant p53 proteins may also differ in their ability to activate transcription (45, 46 ( 10, 23, 47) . The ARO and NPA thyroid carcinoma cell lines represent examples of the former and latter, respectively, and suggest that both these p53 mutation profiles can provide growth advantage to thyroid tumor cells.
Over the past few years, a pattern of sequential mutational events which may underlie initiation and progression of thyroid neoplasia is becoming apparent (2-9). The model proposed by Fearon and Vogelstein (48) for colon tumorigenesis appears to be also applicable to thyroid neoplasms, although the genes involved in the phenotypic progression differ (Fig.  4) . The studies described in this paper indicate that mutational inactivation of p53 is probably responsible for the progression to the most malignant form of this disease.
